The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
about
Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DTargeted therapies for diarrhea-predominant irritable bowel syndrome.Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.Hemin and Zinc Protoporphyrin IX Affect Granisetron Constipating Effects In Vitro and In Vivo.A review of ischemic colitis: is our clinical recognition and management adequate?Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS.Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints.ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI).Impact of persistent constipation on health-related quality of life and mortality in older community-dwelling women.Acute Lower Gastrointestinal Bleeding: Characteristics and Clinical Outcome of Patients Treated With an Intensive Protocol.Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.
P2860
Q33656496-01CC6D67-99A9-4CED-84E9-320B46855291Q33667183-46576826-F89B-4ECF-9E96-F249BCD5264DQ36065945-B482ACC7-B046-4E48-92B9-04BEA7E1A503Q36072690-9BCC8061-DB85-4BBB-ABDE-02CA4406827AQ36995261-DE4F5CF1-F5C7-4526-A40C-FF2D96AB8183Q38144152-CB7A165E-0868-4B65-BF82-C4758ED4F2DBQ38175457-19DCEB89-C11C-442E-84C4-0F1A6C2A8262Q38180026-DE20399C-EAE3-4AA6-9CEB-4ACE7F9C2012Q42408269-66D31950-00F9-429A-8594-EE6834CB580EQ46195549-EE15E68F-FC3D-4A35-9000-983BC2CA1176Q48244678-8150EF87-FD62-466C-9208-36B9C4CAC49CQ49259534-CDDE4756-7B56-4411-B1DB-E3362B09144DQ51072387-D995F2E7-B458-4279-BD4B-D4FBF04638F3
P2860
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The risk of ischaemic colitis ...... d with serotonergic therapies.
@en
The risk of ischaemic colitis ...... d with serotonergic therapies.
@nl
type
label
The risk of ischaemic colitis ...... d with serotonergic therapies.
@en
The risk of ischaemic colitis ...... d with serotonergic therapies.
@nl
prefLabel
The risk of ischaemic colitis ...... d with serotonergic therapies.
@en
The risk of ischaemic colitis ...... d with serotonergic therapies.
@nl
P2860
P1433
P1476
The risk of ischaemic colitis ...... d with serotonergic therapies.
@en
P2093
James H Lewis
P2860
P304
P356
10.2165/11590690-000000000-00000
P577
2011-07-01T00:00:00Z
P6179
1052449078